De-risking Drug Development | Episode 2: Focus on safety and efficacy and prove quickly that your product works

De-risking Drug Development is a five-part podcast series that explores the business-critical decisions that take place at each stage of the drug development process. We know that novel therapies often don’t meet their revenue expectations, but through informed decision-making, you can minimize risk and maximize the probability of commercial success.

In episode two we discuss the critical decision points in early phase development (phase I to IIa) that can ultimately determine the success of your product. Specifically, we discuss why drugs fail at this early stage, focusing on safety, tolerability and efficacy. We focus on the importance of integrated clinical development planning, with our experts' informed perspectives on regulatory, feasibility and early phase requirements.  Our discussion covers how risk can be mitigated, and key takeaways that biotech leaders should - but often don't - consider in early phase development. 

Episode 1: Determine how to drive value in pre-clinical development
Episode 2: Focus on safety and efficacy and prove quickly that your product works 
Episode 3: Plan how to get to market quickly, post-proof of concept 
Episode 4: Implement market launch strategy, pre-approval
Episode 5: Expand the use and value of your product over time
 

Return to Insights Center